Answers are grounded in this paper and cite their sources.
We enjoyed reading the article by Alimoradi et al titled “Metformin Exhibits Anti-Inflammatory Effects by Regulating microRNA-451/CXCL16 and B Cell Leukemia/Lymphoma 2 in Patients With Osteoarthritis” and would like to offer additional commentary on the potential of metformin as an anti-inflammatory therapeutic in osteoarthritis (OA) management.1 We hope these perspectives may provide insight into areas that may require further research and improvement. Alimoradi et al1 reported that metformin mediates anti-inflammatory effects through the regulation of microRNA-451 and CXCL16 expression, highlighting its impact on pathways that influence B cell leukemia/lymphoma 2 (BCL-2) protein levels. They found that metformin reduced markers of inflammation in patients with OA, suggesting a potential role for this common antidiabetic medication in managing OA beyond glycemic control. The article calls for further investigation into the molecular pathways involved and concluded that metformin could play a dual role in managing OA symptoms through anti-inflammatory mechanisms. The effect it had on the inflammatory pathways—even through the modulation of microRNA-451—has been an assured avenue of therapy in the management of OA. Recent reviews, including one by Kristófi and Eriksson,2 emphasize that the anti-inflammatory activity in this drug is mediated through activation of AMP kinase and, in turn, inhibiting mechanistic target of rapamycin and NF-κB, both important signaling pathways in inflammation. This delineates support for the findings of the article on microRNA-451 indicating that metformin holds promise in reducing inflammation by modulating microRNA pathways.2 The article also confirms the results by Alimoradi et al,3 who stated that metformin reduced the symptoms of OA by especially taking into consideration genetic parameters, such as BCL-2 and CXCL16 polymorphisms, affecting inflammatory and apoptotic pathways. They observed a marked improvement in pain, daily activities, and quality of life among their patients with OA who were being treated with metformin in a double-blind placebo-controlled study. Although this is methodologically sound, a more heterogeneous population with longer follow-up would greatly enhance the generalizability of findings. This study would be further enhanced by the addition of objective measures of inflammation alongside patient-reported outcomes.3 Apart from that, Kim et al4 reviewed the additional use of metformin in several autoimmune inflammatory rheumatic diseases other than OA. Their review emphasizes how the activation of AMP-activated protein kinase by metformin can influence immune cell functions and inflammatory responses, including those specific to OA. These results indicate that, besides alleviating the symptoms, metformin acts at the very root of OA inflammation that leads to the advancement of the disease. This perspective is a reinforcement that therapeutic benefits from metformin go beyond glucose regulation, thus making it a worthy treatment modality in the management of inflammatory diseases such as OA.4 Ultimately, this article presents a timely and relevant investigation into the molecular mechanisms of OA and highlights the value of repurposing existing medications for inflammatory conditions. The study broadens our understanding of metformin's impact on OA management and encourages further exploration of anti-inflammatory therapeutics for improved patient outcomes. We applaud the authors for not only emphasizing the importance of microRNA and CXCL16 regulation in OA but also establishing a basis for future studies on anti-inflammatory pathways in joint disease management. We look forward to reading about future studies that provide additional insight into these therapeutic mechanisms.
No takes yet. Share an insight, caveat, or question.
La et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: